These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7940890)

  • 1. Gastrointestinal, hepatorenal, and neuromuscular toxicity caused by cyclosporine-colchicine interaction in renal transplantation.
    Yussim A; Bar-Nathan N; Lustig S; Shaharabani E; Geier E; Shmuely D; Nakache R; Shapira Z
    Transplant Proc; 1994 Oct; 26(5):2825-6. PubMed ID: 7940890
    [No Abstract]   [Full Text] [Related]  

  • 2. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients.
    Kahan BD; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander JW; Chang C; Choc M
    Transplant Proc; 1994 Oct; 26(5):2940-3. PubMed ID: 7940928
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine.
    Minetti EE; Minetti L
    J Nephrol; 2003; 16(3):421-5. PubMed ID: 12832745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: results after 1 month.
    Neumayer HH; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J
    Transplant Proc; 1994 Oct; 26(5):2944-8. PubMed ID: 7940929
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
    Hecking M; Kainz A; Schillinger M; Posch C; Birsan T; Rasoul-Rockenschaub S; Böhmig GA; Schmaldienst S; Watschinger B; Hörl WH; Mühlbacher F; Säemann MD
    Transpl Int; 2008 Mar; 21(3):223-33. PubMed ID: 17903183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters.
    Vollenbroeker B; Koch JH; Fobker M; Suwelack B; Hohage H; Müller U
    Transplant Proc; 2005 May; 37(4):1741-4. PubMed ID: 15919451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between glipizide and cyclosporine: report of two cases.
    Chidester PD; Connito DJ
    Transplant Proc; 1993 Apr; 25(2):2136-7. PubMed ID: 8470294
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
    Vathsala A; Lee WT; Jacob E; Woo KT
    Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-containment strategies in transplantation: the utility of cyclosporine-ketoconazole combination therapy.
    Odocha O; Kelly B; Trimble S; Murigande C; Toussaint RM; Callender CO
    Transplant Proc; 1996 Apr; 28(2):907-9. PubMed ID: 8623456
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of liver disease in kidney transplant recipients on cyclosporine dose and metabolite levels.
    Alfurayh O; Sobh M; Minhas M; Almeshari K; Alshaibani K; Qunibi W; Aesha H; Taher S
    Transplant Proc; 1994 Oct; 26(5):2655. PubMed ID: 7940830
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout.
    Wallace SL; Singer JZ; Duncan GJ; Wigley FM; Kuncl RW
    J Rheumatol; 1991 Feb; 18(2):264-9. PubMed ID: 2023222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical study of sandimmun neoral in cadaveric renal transplantation.
    Xue W; Chen Y; Xing J; Tian P
    Transplant Proc; 1996 Jun; 28(3):1333-4. PubMed ID: 8658682
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of cyclosporine metabolites and clinical toxicity in organ transplantation.
    Soy D; Campistol JM; Brunet M; Roca M; Carreras E; Andreu H; Codina C; Ribas J
    Transplant Proc; 1995 Aug; 27(4):2415-6. PubMed ID: 7652858
    [No Abstract]   [Full Text] [Related]  

  • 14. Colchicine: serious interactions.
    Prescrire Int; 2008 Aug; 17(96):151-3. PubMed ID: 19492485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing cyclosporine A nephrotoxicity and rejection late after adult liver transplantation.
    Paul A; Levy GA; Greig PD
    Transplant Proc; 1993 Aug; 25(4):2664-5. PubMed ID: 8356714
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of tolerability, safety, and efficacy of cyclosporine microemulsion in renal transplant recipients.
    Gracida C; Melchor JL; Miranda ME; Bartolano C
    Transplant Proc; 1996 Aug; 28(4):2171-3. PubMed ID: 8769191
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk assessment of cadmium toxicity on hepatic and renal tissues of rats.
    Novelli EL; Vieira EP; Rodrigues NL; Ribas BO
    Environ Res; 1998 Nov; 79(2):102-5. PubMed ID: 9841808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine monotherapy as primary immunosuppression in renal transplantation--five-year experience.
    Andreu J; Campistol JM; Oppenheimer F; Torregrosa V; Ricart MJ; Vilardell J; Carretero P
    Transplant Proc; 1994 Feb; 26(1):337-40. PubMed ID: 8109006
    [No Abstract]   [Full Text] [Related]  

  • 19. Muscle weakness due to colchicine in a renal transplant recipient.
    Jagose JT; Bailey RR
    N Z Med J; 1997 Sep; 110(1051):343. PubMed ID: 9323377
    [No Abstract]   [Full Text] [Related]  

  • 20. Gout, bradycardia, and hypercholesterolemia after renal transplantation.
    Kelleher SP; Davis WR; Paraskevopoulos N
    South Med J; 2001 Jul; 94(7):732-4. PubMed ID: 11531183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.